Organizations publish recommendations for identifying and reporting hypoglycemia in clinical studies.

How comfortable are you in recommending the combination of a GLP-1 receptor agonist along with glargine insulin? 1- Very comfortable 2- Slightly comfortable 3- Neutral 4- Slightly uncomfortable 5- Very uncomfortable at this time Follow the link to share your response and see what your colleagues think!

Please select the drug class that best fits the description. This injectable drug class leads to increased insulin secretion, decreased glucagon secretion and slowed gastric emptying. One of its advantages is that its use can lead to weight loss: 1. DPP-4 inhibitors 2. GLP-1 receptor agonists 3. Dopamine-2 Agonists 4. SGLT-2 Inhibitors Did you get it right? Follow the link to find out!

Woman, 42 years of age. Type 1 diabetes for the past 22 years. I’ve been working with her and reviewing her CGM reports, and teaching about checking patterns before making changes in her pump settings.

Physiologic effects of incretin hormones: GLP-1 -- The GLP-1 receptor has been detected on numerous organs and tissues. High levels of GLP-1 receptors have been found on pancreatic beta cells, delta cells, endothelial cells, cardiomyocytes, the gastrointestinal tract, and the kidneys.

Premarket Approval application submitted for Eversense® CGM system.

Sucralose may adversely affect glucose metabolism.

Two products approved by FDA will be available in 2017.

David Kliff, of the Diabetes Investor newsletter, attempts to explain why the cost of insulin is so high and how to solve the problem.

This injectable drug class focuses on the incretin system and leads to increased insulin secretion, decreased glucagon secretion, and slowed gastric emptying. One of its advantages is that its use can lead to weight loss: 1. GLP-1 receptor agonists 2. SGLT-2 Inhibitors 3. DPP-IV 4. Sulfonylureas Did you get the right answer? Follow the link to find out!